Roche said its Lunsumio drug to combat lymphoma, alongside another medicine, might be effective in earlier treatment lines for forms of the disease.

"Epcoritamab and R 2 is a novel chemotherapy-free fixed-duration therapy that is suitable for outpatient administration and, ...

New three-year follow-up results from the TRANSCEND FL trial show that patients with relapsed or refractory follicular ...

Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the ...

The decision to use newer agents in relapsed/refractory follicular lymphoma is heavily influenced by the disease’s inherent ...

A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may ...

Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial Patients received induction ...

Clinicians treating follicular lymphoma face a critical sequencing concern: whether prior CD19-directed therapies cause the loss or downregulation of the CD19 antigen, which is required for effective ...

A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may ...

Jones anchored her discussion in a core philosophy for veterinary oncology: "one size does not fit all.” According to Jones, ...